Abstract

BackgroundBariatric surgery is an effective treatment for morbid obesity and glycaemic dysfunction.ObjectivesThe aim of the work was to examine both the static and dynamic changes of glucose-insulin homeostasis and incretin hormone response following sleeve gastrectomy (SG) in a sample of 55 participants preoperatively and 1 month and 6 months postoperatively. The focus was on a sample of patients with impaired glucose tolerance and type 2 diabetes (T2D).SettingMorriston Hospital, UK.MethodsProspective study comprising of 55 participants with impaired glucose homeostasis and T2D undergoing SG (mean body mass index [BMI] 50.4 kg/m2, mean glycated haemoglobin [A1C] 7.4%). Serial measurements of glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) were performed during oral glucose tolerance testing preoperatively and 1 and 6 months postoperatively. Areas under the curve (AUC) were examined at 30, 60, and 120 min.ResultsWe observed significant improvements in measures of obesity, as well as static and dynamic measures of glucose, insulin, C-peptide and HOMA. Furthermore, significant increases in GLP-1 response as early as 6 months postoperatively were also seen.ConclusionsTo our knowledge, no study has examined the detailed dynamic changes in glucose and insulin homeostasis in this number of participants undergoing SG in relation to incretin hormones GIP and GLP-1. This current study supports the role of SG for the treatment of obesity-related glucose dysregulation.

Highlights

  • Obesity is associated with a number of co-morbidities including diabetes, cardiovascular disease, hypertension and osteoarthritis [1]

  • Bariatric surgery is an effective treatment for morbid obesity and is associated with at least 80% remission of impaired glucose tolerance (IGT) and type 2 diabetes (T2D) [3,4,5,6,7]

  • Published studies include samples with a small number of participants and lack detailed analysis of dynamic measures of insulin-glucose homeostasis and incretin hormones conducted during an oral glucose tolerance test (OGTT)

Read more

Summary

Introduction

Obesity is associated with a number of co-morbidities including diabetes, cardiovascular disease, hypertension and osteoarthritis [1]. Bariatric surgery is an effective treatment for morbid obesity and is associated with at least 80% remission of impaired glucose tolerance (IGT) and type 2 diabetes (T2D) [3,4,5,6,7]. The SG procedure requires the removal of gastric cells that produce orexigenic hormones and may be associated with changes in incretin hormones. These anatomical and physiological changes may explain its superiority over other restrictive procedures in the management of excess weight and impaired glucose regulation [8, 9]. Bariatric surgery is an effective treatment for morbid obesity and glycaemic dysfunction

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call